Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Haematologica
|
June 24, 2021
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
Sara Napoli, Luciano Cascione, Andrea Rinaldi, et al.
Cancer Research Communications
|
April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Zoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Nature Communications
|
May 31, 2017
A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers
Giuseppina Pisignano, Sara Napoli, Marco Magistri, et al.
Haematologica
|
December 15, 2018
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu, Serena Ferraresso, Laura Marconato, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Haematologica
|
June 24, 2021
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
Sara Napoli, Luciano Cascione, Andrea Rinaldi, et al.
Cancer Research Communications
|
April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Zoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Nature Communications
|
May 31, 2017
A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers
Giuseppina Pisignano, Sara Napoli, Marco Magistri, et al.
Haematologica
|
December 15, 2018
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu, Serena Ferraresso, Laura Marconato, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 5